AKT1 and hepatocellular carcinoma: We also observed a similar dose-dependent NPTX1 regulation trend in HCC cells treated with the AKT inhibitor GSK2141795 (Figure 5B), which indicate that the expression of NPTX1 might be modulated by the AKT signaling pathway in HCC.